Patents by Inventor Daniel Zamanillo Castanedo

Daniel Zamanillo Castanedo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190142840
    Abstract: The invention relates to compounds of general formula (I) having pharmacological activity towards the sigma receptor, for use in decreasing cancer cells proliferation and improving chemotherapeutic drug efficacy.
    Type: Application
    Filed: June 5, 2017
    Publication date: May 16, 2019
    Inventors: Daniel ZAMANILLO-CASTANEDO, José-Carlos PRADOS-SALAZAR, Sebastiá VIDELA-CÉS, José-Miguel VELA-HERNÁNDEZ, Carlos-Ramón PLATA-SALAMAN, Jordi BRUNA-ESCUER
  • Publication number: 20190010128
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Application
    Filed: February 1, 2018
    Publication date: January 10, 2019
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Patent number: 9931346
    Abstract: The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: April 3, 2018
    Assignee: LABORATORIOS DEL DR. ESTEVE S.A.
    Inventors: Daniel Zamanillo-Castanedo, Enrique Portillo-Salido
  • Patent number: 9914705
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: March 13, 2018
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Publication number: 20180021309
    Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (1) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
    Type: Application
    Filed: August 3, 2017
    Publication date: January 25, 2018
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Miguel VELA HERNANDEZ, Daniel ZAMANILLO-CASTANEDO
  • Patent number: 9844516
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: December 19, 2017
    Assignee: Laboratorios De Dr. Esteve
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
  • Patent number: 9789115
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: October 17, 2017
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Margarita Puig Riera de Conias
  • Patent number: 9782483
    Abstract: The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: October 10, 2017
    Assignee: Laboratories Del Dr. Esteve, S.A.
    Inventors: José Miguel Vela Hernández, Xavier Codony-Soler, Daniel Zamanillo-Castanedo
  • Publication number: 20170273948
    Abstract: The invention relates to compounds of formula (I) or formula (II) having pharmacological activity towards the sigma receptor, for use in the treatment or prevention of osteoarthritis and pain due to osteoarthritis.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 28, 2017
    Inventors: José Miguel VELA HERNÁNDEZ, Manuel MERLOS-ROCA, Daniel ZAMANILLO-CASTANEDO
  • Patent number: 9757358
    Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 12, 2017
    Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Miguel Vela Hernández, Daniel Zamanillo-Castanedo
  • Publication number: 20170112829
    Abstract: The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy.
    Type: Application
    Filed: January 10, 2017
    Publication date: April 27, 2017
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut H. Buschmann, José-Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo, Francisco Rafael Nieto-López
  • Publication number: 20160310501
    Abstract: The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Gabapentinoid, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.
    Type: Application
    Filed: December 16, 2014
    Publication date: October 27, 2016
    Inventors: Daniel ZAMANILLO-CASTANEDO, Enrique PORTILLO-SALIDO
  • Publication number: 20160310500
    Abstract: The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.
    Type: Application
    Filed: December 16, 2014
    Publication date: October 27, 2016
    Inventors: Daniel ZAMANILLO-CASTANEDO, Enrique PORTILLO-SALIDO
  • Publication number: 20160220574
    Abstract: The invention refers to a synergistic combination comprising a Sigma ligand, particularly a Sigma ligand of general formula (I), and NSAID compound, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.
    Type: Application
    Filed: September 11, 2014
    Publication date: August 4, 2016
    Inventors: Daniel ZAMANILLO-CASTANEDO, Enrique PORTILLO-SALIDO, Enrique-José COBOS-DEL-MORAL
  • Publication number: 20160220575
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: April 7, 2016
    Publication date: August 4, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • Publication number: 20160199380
    Abstract: The invention refers to the use of a sigma ligand of formula (I) to prevent or treat pain induced by a chemotherapeutic agent, especially pain induced by taxanes, vinca alkaloids or platinum-containing chemotherapeutic drugs.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 14, 2016
    Applicant: Laboratorios del Dr. Esteve, S.A.
    Inventors: José Manuel Baeyens-Cabrera, Helmut Heinrich Buschmann, José Miguel Vela Hernández, Daniel Zamanillo-Castanedo, Francisco-Rafael Nieto-López
  • Publication number: 20160058771
    Abstract: The invention refers to a combination comprising a Sigma ligand of general formula (I) and alpha-2-adrenergic agonist compound, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain.
    Type: Application
    Filed: April 15, 2014
    Publication date: March 3, 2016
    Inventors: Daniel ZAMANILLO-CASTANEDO, José Miguel VELA HERNÁNDEZ
  • Publication number: 20150018354
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 15, 2015
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela-Hernandez, Daniel Zamanillo-Castanedo
  • Patent number: 8877753
    Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: November 4, 2014
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Daniel Zamanillo-Castanedo
  • Publication number: 20130324535
    Abstract: The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer.
    Type: Application
    Filed: December 2, 2011
    Publication date: December 5, 2013
    Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.
    Inventors: Daniel Zamanillo-Castanedo, José Miguel Vela-Hernández, Carlos Plata-Salaman